BioMarin Pharmaceuticals Inc
BMRN Real Time Price USDRecent trades of BMRN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by BMRN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$390,000 Apr 21, 2025 Issue: Health Issues Medicare/Medicaid Tariff (miscellaneous tariff bills) Taxation/Internal Revenue Code
-
$490,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid
-
$240,000 Oct 21, 2024 Issue: Medicare/Medicaid Health Issues
-
$180,000 Jul 22, 2024 Issue: Medicare/Medicaid Health Issues
-
$410,000 Apr 22, 2024 Issue: Medicare/Medicaid Health Issues
-
$470,000 Jan 22, 2024 Issue: Medicare/Medicaid Health Issues
-
$220,000 Oct 20, 2023 Issue: Medicare/Medicaid Health Issues
-
$210,000 Jul 20, 2023 Issue: Medicare/Medicaid Health Issues
-
$420,000 Jan 20, 2023 Issue: Medicare/Medicaid Health Issues
-
$170,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$220,000 Jul 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues
-
$560,000 Apr 20, 2022 Issue: Medicare/Medicaid Health Issues
-
$270,000 Jan 20, 2022 Issue: Immigration Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$190,000 Oct 20, 2021 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$190,000 Jul 20, 2021 Issue: Health Issues Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code
-
$390,000 Apr 20, 2021 Issue: Immigration Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$510,000 Jan 21, 2021 Issue: Immigration Medicare/Medicaid Health Issues
-
$230,000 Oct 20, 2020 Issue: Immigration Medicare/Medicaid Health Issues
-
$250,000 Jul 20, 2020 Issue: Medicare/Medicaid Health Issues Budget/Appropriations
-
$370,000 Apr 20, 2020 Issue: Medicare/Medicaid Health Issues
-
$390,000 Jan 21, 2020 Issue: Immigration Health Issues Medicare/Medicaid
-
$160,000 Oct 21, 2019 Issue: Health Issues Medicare/Medicaid Trade (domestic/foreign) Immigration
-
$110,000 Jul 22, 2019 Issue: Medicare/Medicaid Health Issues
-
$410,000 Apr 22, 2019 Issue: Health Issues Medicare/Medicaid
-
$340,000 Jan 22, 2019 Issue: Medicare/Medicaid Health Issues
-
$120,000 Oct 22, 2018 Issue: Health Issues Medicare/Medicaid
-
$110,000 Jul 20, 2018 Issue: Medicare/Medicaid Health Issues
-
$250,000 Apr 20, 2018 Issue: Health Issues
-
$290,000 Jan 22, 2018 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$150,000 Oct 20, 2017 Issue: Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$350,000 Jul 20, 2017 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$280,000 Jul 20, 2017 Issue: Budget/Appropriations Health Issues Taxation/Internal Revenue Code Medicare/Medicaid
-
$210,000 Jan 23, 2017 Issue: Health Issues
-
$120,000 Oct 20, 2016 Issue: Medicare/Medicaid Health Issues
-
$90,000 Jul 20, 2016 Issue: Health Issues
-
$80,000 Apr 20, 2016 Issue: Health Issues
-
$60,000 Jan 20, 2016 Issue: Health Issues
-
$60,000 Oct 20, 2015 Issue: Health Issues
-
$50,000 Jul 20, 2015 Issue: Health Issues Trade (domestic/foreign)
-
$60,000 Apr 20, 2015 Issue: Taxation/Internal Revenue Code Health Issues
-
$120,000 Jan 20, 2015 Issue: Health Issues Taxation/Internal Revenue Code
-
$50,000 Oct 21, 2014 Issue: Taxation/Internal Revenue Code Health Issues
-
$60,000 Jul 21, 2014 Issue: Taxation/Internal Revenue Code Health Issues
-
$60,000 Apr 21, 2014 Issue: Health Issues
-
$30,000 Jan 21, 2014 Issue: Health Issues
-
$30,000 Oct 21, 2013 Issue: Taxation/Internal Revenue Code Pharmacy
-
$10,000 Jul 22, 2013 Issue: Taxation/Internal Revenue Code Health Issues
-
$80,000 Oct 20, 2009 Issue: Health Issues
Estimated quarterly lobbying spending
BMRN Revenue by Segment or Geography
New patents grants
-
Patent Title: Adeno-associated virus factor viii vectors Mar. 04, 2025
-
Patent Title: C-type natriuretic peptide variants to treat skeletal dysplasia in children Feb. 25, 2025
-
Patent Title: Use of c-type natriuretic peptide variants to treat osteoarthritis Feb. 04, 2025
-
Patent Title: Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof Jan. 07, 2025
-
Patent Title: Use of c-type natriuretic peptide variants to treat skeletal dysplasia Sep. 03, 2024
-
Patent Title: Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects Mar. 05, 2024
-
Patent Title: Use of c-type natriuretic peptide variants to treat skeletal dysplasia Feb. 27, 2024
-
Patent Title: Liver targeting adeno-associated viral vectors Nov. 21, 2023
-
Patent Title: Methods of treating phenylketonuria Aug. 29, 2023
-
Patent Title: Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same Jul. 04, 2023
-
Patent Title: Use of c-type natriuretic peptide variants to treat skeletal dysplasia Feb. 28, 2023
-
Patent Title: Adeno-associated virus capsid proteins Feb. 21, 2023
-
Patent Title: Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof Nov. 22, 2022
-
Patent Title: Adeno-associated virus factor viii vectors Aug. 09, 2022
-
Patent Title: Glycolate oxidase inhibitors for the treatment of disease Jul. 12, 2022
-
Patent Title: N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors Jun. 14, 2022
-
Patent Title: Lysosomal targeting peptides and uses thereof Jun. 07, 2022
-
Patent Title: Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof May. 31, 2022
-
Patent Title: Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes Mar. 01, 2022
-
Patent Title: Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof Feb. 22, 2022
-
Patent Title: Tpp-1 formulations and methods for treating cln2 disease Jan. 25, 2022
-
Patent Title: Use of c-type natriuretic peptide variants to treat osteoarthritis Dec. 21, 2021
-
Patent Title: Delivery of therapeutic compounds to the brain and other tissues Jun. 22, 2021
-
Patent Title: Histone deacetylase inhibitors Apr. 20, 2021
-
Patent Title: Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof Mar. 02, 2021
-
Patent Title: Histone deacetylase inhibitors Dec. 01, 2020
-
Patent Title: Variants of c-type natriuretic peptide Oct. 20, 2020
-
Patent Title: Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition Oct. 06, 2020
-
Patent Title: Tpp-1 formulations and methods for treating cln2 disease Sep. 01, 2020
-
Patent Title: Detection of oligosaccharides Jun. 16, 2020
-
Patent Title: Methods of diagnosing mucopolysaccharidosis (mps) i and methods of monitoring treatment of mps by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker Jun. 09, 2020
-
Patent Title: Use of c-type natriuretic peptide variants to treat skeletal dysplasia May. 12, 2020
-
Patent Title: Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof Feb. 18, 2020
-
Patent Title: Histone deacetylase inhibitors Jan. 07, 2020
-
Patent Title: Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same Dec. 24, 2019
-
Patent Title: Adeno-associated virus factor viii vectors Nov. 05, 2019
-
Patent Title: Hdac inhibitors Oct. 01, 2019
-
Patent Title: Histone deacetylase inhibitors Jun. 04, 2019
-
Patent Title: Nucleic acids encoding targeted therapeutic lysosomal enzyme fusion proteins May. 28, 2019
-
Patent Title: Histone deacetylase inhibitors May. 28, 2019
-
Patent Title: Targeted therapeutic proteins May. 28, 2019
-
Patent Title: Histone deacetylase inhibitors May. 07, 2019
-
Patent Title: Tpp-1 formulations and methods for treating cln2 disease May. 07, 2019
-
Patent Title: Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition Apr. 16, 2019
-
Patent Title: N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors Mar. 26, 2019
-
Patent Title: Glucosylceramide synthase inhibitors for the treatment of diseases Mar. 12, 2019
-
Patent Title: Glucosylceramide synthase inhibitors for the treatment of diseases Mar. 12, 2019
-
Patent Title: Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof Mar. 05, 2019
-
Patent Title: Histone deacetylase inhibitors Aug. 28, 2018
-
Patent Title: Hdac inhibitors Jul. 24, 2018
Federal grants, loans, and purchases
- $142,074 2022-04-05 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2021-10-14 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $15,705 2021-10-13 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $26,175 2021-07-29 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2021-05-20 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Estimated quarterly amount awarded from public contracts
Recent insights relating to BMRN
Recent picks made for BMRN stock on CNBC
ETFs with the largest estimated holdings in BMRN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $BMRN stock a Buy, Sell, or Hold?
- What is the price target for $BMRN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $BMRN stock?
- Who owns the most shares of $BMRN stock?
- What funds own $BMRN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view BMRN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.